We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

158 hedge funds and large institutions have $950M invested in Achillion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 43 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $37.5M | Put options by funds: $18.6M

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

44% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 43

8% less capital invested

Capital invested by funds: $1.03B → $950M (-$85.3M)

9% less funds holding

Funds holding: 173158 (-15)

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

Holders
158
Holders Change
-15
Holders Change %
-8.67%
% of All Funds
4.26%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
26
Increased
62
Reduced
43
Closed
41
Calls
$37.5M
Puts
$18.6M
Net Calls
+$18.9M
Net Calls Change
-$9.18M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$88.1M +$16.4M +1,738,467 +21%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$85.5M -$4.59M -485,453 -5%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$78.6M
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$74.3M +$79.3M +8,388,200 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$61M +$3.96M +418,588 +6%
JHIU
6
Janus Henderson Investors US
Colorado
$57M +$17.1M +1,803,126 +39%
State Street
7
State Street
Massachusetts
$44.1M +$11.5M +1,217,690 +32%
BFA
8
BlackRock Fund Advisors
California
$38.4M -$1.94M -205,121 -5%
AllianceBernstein
9
AllianceBernstein
Tennessee
$32.4M +$357K +37,751 +1%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$26.7M +$1.66M +175,000 +6%
BIT
11
BlackRock Institutional Trust
California
$24.1M -$1.5M -158,528 -6%
Goldman Sachs
12
Goldman Sachs
New York
$22.4M -$6.01M -635,363 -20%
RI
13
RTW Investments
New York
$22.3M +$8.44M +892,800 +55%
DCM
14
Discovery Capital Management
Connecticut
$18.1M +$6.59M +696,271 +52%
EAM
15
EverPoint Asset Management
Connecticut
$16.4M +$17.5M +1,850,000 New
BBA
16
Baker Bros. Advisors
New York
$13.5M +$12.4M +1,309,502 +611%
BB
17
BB Biotech
Switzerland
$11.3M
Northern Trust
18
Northern Trust
Illinois
$10.9M -$401K -42,372 -3%
JP Morgan Chase
19
JP Morgan Chase
New York
$9.93M +$4.58M +484,276 +76%
RSCM
20
Rock Springs Capital Management
Maryland
$9.75M +$4.73M +500,000 +83%
Bank of America
21
Bank of America
North Carolina
$8.47M +$3.54M +374,460 +64%
SAM
22
Senzar Asset Management
New York
$7.76M +$5.35M +566,100 +183%
Axa
23
Axa
France
$6.69M
SDIC
24
South Dakota Investment Council
South Dakota
$6.12M -$385K -40,700 -6%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$6.1M +$324K +34,247 +5%

ACHN Hedge Fund Activity: Q2 2015 in Review

158 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2015, worth a combined $950M — down 8.2% from $1.03B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of ACHN and 26 opened new positions — a net loss of 15 holders — while 43 trimmed existing stakes and 62 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $79.3M. The largest seller was Sectoral Asset Management, cutting an estimated $29.2M.

  • 158 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2015, down from 173 in Q1 2015.
  • Funds reported $950M of Achillion Pharmaceuticals stock for Q2 2015, down 8.2% quarter-over-quarter.
  • 26 funds opened new Achillion Pharmaceuticals positions in Q2 2015 and 41 closed out, a net change of -15 holders.
  • The largest Achillion Pharmaceuticals buyer in Q2 2015 was Point72 Asset Management, an estimated $79.3M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2015 was Sectoral Asset Management, an estimated $29.2M sold.

Based on aggregated 13F filings for Q2 2015.